Autolus Therapeutics (AUTL) Gains from Investment Securities (2018 - 2025)
Autolus Therapeutics posted quarterly Gains from Investment Securities of $429000.0 for Q4 2025, down 83.59% year-on-year from $2.6 million in Q4 2024, and down 14.37% on a QoQ basis from $501000.0 in Q3 2025.
Autolus Therapeutics (AUTL) has 8 years of Gains from Investment Securities data on file, last reported at $429000.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities fell 83.59% year-over-year to $429000.0; the trailing twelve-month figure through Dec 2025 stood at $2.0 million (down 17.69% YoY), and the FY2025 full-year result was $2.0 million, down 17.69% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at $429000.0, down from $501000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $27.8 million in Q3 2021 and bottomed at -$29.2 million in Q4 2021.
- The 5-year median for Gains from Investment Securities is $39000.0 (2022), against an average of -$5571.4.
- The widest annual swing landed in 2022, when Gains from Investment Securities sank 99.8%; it then soared 12347.62% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$29.2 million in 2021, then surged by 99.82% to -$52000.0 in 2022, then jumped by 140.38% to $21000.0 in 2023, then jumped by 12347.62% to $2.6 million in 2024, then plunged by 83.59% to $429000.0 in 2025.
- The last three Gains from Investment Securities figures came in at $429000.0 (Q4 2025), $501000.0 (Q3 2025), and $1.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Autolus Therapeutics | - | - | -1.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 429,000.00 |
| Dec 31, 2025 | 429,000.00 |
| Sep 30, 2025 | 501,000.00 |
| Sep 30, 2025 | 501,000.00 |
| Jun 30, 2025 | 1.04 Mn |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | -3,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Dec 31, 2024 | 2.61 Mn |
| Dec 31, 2024 | 2.61 Mn |
| Sep 30, 2024 | -223,000.00 |
| Sep 30, 2024 | -223,000.00 |
| Dec 31, 2023 | 21,000.00 |
| Dec 31, 2023 | 21,000.00 |
| Jun 30, 2023 | -23,000.00 |
| Jun 30, 2023 | -23,000.00 |
| Mar 31, 2023 | -3.77 Mn |
| Mar 31, 2023 | -3.77 Mn |
| Dec 31, 2022 | -52,000.00 |
| Dec 31, 2022 | -52,000.00 |
| Sep 30, 2022 | 57,000.00 |
| Sep 30, 2022 | 57,000.00 |
| Dec 31, 2021 | -29.19 Mn |
| Dec 31, 2021 | -29.19 Mn |
| Sep 30, 2021 | 27.85 Mn |
| Sep 30, 2021 | 27.85 Mn |
| Mar 31, 2021 | 672,000.00 |
| Mar 31, 2021 | 672,000.00 |
| Dec 31, 2020 | -19.78 Mn |
| Dec 31, 2020 | -19.78 Mn |
| Jun 30, 2019 | 43,000.00 |
| Jun 30, 2019 | 43,000.00 |
| Mar 31, 2019 | 43,000.00 |
| Mar 31, 2019 | 43,000.00 |
| Sep 30, 2018 | 8,000.00 |
| Sep 30, 2018 | 8,000.00 |